Cutter Capital Management LP recently acquired 295,000 shares in Bristol Myers Squibb, valued at nearly $18 million. The purchase took place during the first quarter, as revealed by the fund’s 13F filing with the Securities & Exchange Commission.

Mubadala Investment Co PJSC has trimmed its position in Gilead Sciences by 2.6%, according to a Form 13F filing with the SEC. The institutional investor sold 1,160 shares during the first quarter, retaining 42,748 shares of the biopharmaceutical firm.